Biosensors in Parkinson's disease

Clin Chim Acta. 2021 Jul:518:51-58. doi: 10.1016/j.cca.2021.03.009. Epub 2021 Mar 19.

Abstract

Parkinson's disease (PD) is one of the most critical disorders of the elderly and strongly associated with increased disability, and reduced quality of life. PD is a progressive neurodegenerative disease affecting more than six million people worldwide. Evaluation of clinical manifestations, as well as movement disorders by a neurologist and some routine laboratory tests are the most important diagnostic methods for PD. However, routine and old methods have several disadvantages and limitations such as low sensitivity and selectivity, high cost, and need for advanced equipment. Biosensors technology opens up new diagnoses approach for PD with the use of a new platform that allows reliable, repeatable, and multidimensional identification to be made with minimal problem and discomfort for patients. For instance, biosensing systems can provide promising tools for PD treatment and monitoring. Amongst biosensor technology, electrochemical techniques have been at the frontline of this progress, thanks to the developments in material science, such as gold nanoparticles (AuNPs), quantum dots (QDs), and carbon nanotubes (CNTs). This paper evaluates the latest progress in electrochemical and optical biosensors for PD diagnosis.

Keywords: Alpha-synuclein (a-Syn); Biosensors; LOD; Linear range; Parkinson’s disease (PD).

Publication types

  • Review

MeSH terms

  • Aged
  • Biosensing Techniques*
  • Gold
  • Humans
  • Metal Nanoparticles*
  • Nanotubes, Carbon*
  • Neurodegenerative Diseases*
  • Parkinson Disease* / diagnosis
  • Quality of Life
  • alpha-Synuclein

Substances

  • Nanotubes, Carbon
  • alpha-Synuclein
  • Gold